Dynavax Technologies Co. (NASDAQ:DVAX) has been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $27.40.
A number of equities research analysts have recently issued reports on DVAX shares. BidaskClub downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, March 27th. Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st. JPMorgan Chase downgraded shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. Finally, Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th.
In related news, insider David F. Novack sold 34,214 shares of Dynavax Technologies stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $16.52, for a total transaction of $565,215.28. Following the transaction, the insider now owns 21,613 shares in the company, valued at approximately $357,046.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David F. Novack sold 2,121 shares of Dynavax Technologies stock in a transaction on Friday, March 9th. The shares were sold at an average price of $17.97, for a total transaction of $38,114.37. Following the transaction, the insider now owns 77,192 shares in the company, valued at approximately $1,387,140.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,444 shares of company stock worth $865,906. 2.90% of the stock is owned by corporate insiders.
NASDAQ:DVAX opened at $18.55 on Friday. Dynavax Technologies has a 12 month low of $5.05 and a 12 month high of $24.45. The company has a market capitalization of $1,205.86, a price-to-earnings ratio of -10.72 and a beta of 0.84.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.32). Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.53 million. equities analysts expect that Dynavax Technologies will post -1.91 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3336622/dynavax-technologies-co-dvax-receives-consensus-rating-of-buy-from-brokerages.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.